CAP Publishes Guideline for PD-L1 Testing of Lung Cancer Patients
CAP developed recommendations for testing immunotherapy biomarkers, such as PD-L1 and TM), in patients with NSCLC.
CAP developed recommendations for testing immunotherapy biomarkers, such as PD-L1 and TM), in patients with NSCLC.
Clinical validation data shows that Veracyte's Percepta Nasal Swab test determines lung cancer risk with high accuracy for certain patients.
Millions of Americans with tobacco-related lung disease have symptoms that do not fit any existing tobacco-related disease criteria.
New data demonstrates Exai Bio’s novel RNA- and AI-based platform detected non-small cell lung cancer with high accuracy.
Read MoreThe FDA approved the VENTANA PD-L1 (SP263) Assay as a CDx to identify NSCLC patients eligible for treatment with Libtayo (cemiplimab).
Read MoreThe Q-submission phase is a regulatory step which allows regular and in-depth discussions with the FDA on key topics.
Read MoreLucence announced that Palmetto GBA finalized a foundational local coverage determination (LCD) for the LiquidHALLMARKassay.
Read MoreOncoHost, a diagnostics company centered on predictive biomarker development patient care, launched its non-small lung cancer (NSCLC) test.
Read MoreThermo Fisher Scientific is working with AstraZeneca to develop a solid tissue and blood-based companion diagnostic test for Tagrisso.
Read MoreThe liquid biopsy ctDx FIRST test is FDA approved as a companion diagnostic for advanced non-small cell lung cancer (NSCLC) patients.
Read MoreMicronoma announced its OncobiotaLUNG assay received the Breakthrough Device Designation from the U.S. FDA for lung carcinoma detection.
Read MorePrognomiQ unveiled results from multi-omics study demonstrating the power of diverse molecular biomarkers in the early cancer detection.
Read MoreAgilent Technologies announced that the FDA has approved the ctDx FIRST as a companion diagnostic to identify advanced NSCLC.
Read MoreImplementing lung cancer screening at four diverse healthcare systems resulted in a 6.6% decrease in Stage IV disease.
Read MoreA new collaborative project has successfully demonstrated a superior ability to detect circulating tumor DNA (ctDNA) from saliva.
Read MoreENHERTU is a specifically engineered HER2 directed antibody drug conjugate developed and commercialized by Daiichi Sankyo and AstraZeneca.
Read MoreResearchers have found a blood biomarker that can complement LDCT by distinguishing NSCLC from benign nodules without an invasive biopsy.
Read MoreMedial EarlySign signed a new partnership with Roche to create innovative, evidence-based solutions for early detection of lung cancer.
Read More